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Introduction 49
The human corpus luteum (CL) is a transient endocrine gland that develops from the dominant 50 follicle after ovulation. It produces large amounts of progesterone, which is essential for 51 blastocyst implantation, maintenance of pregnancy, and preservation of the structure and 52 function of the CL itself (1). The production of progesterone by the CL is dependent on 53 luteinizing hormone (LH) secretion from the pituitary gland, which binds to 54 LH/choriogonadotropin receptor (LHCGR) on the surface of granulosa lutein and theca lutein 55 cells (2). Human chorionic gonadotropin (hCG) secreted from the developing conceptus also 56 binds to LHCGR and activates intracellular signaling pathways to maintain progesterone 57 secretion, suppress luteolytic molecules, and rescue the CL from degradation during early 58 pregnancy (3, 4). 59 In a non-conception cycle, the CL starts to regress via a degradation process known as 60 luteolysis. This involves a loss of both the functional and structural integrity of the CL where 61 progesterone production declines, and the CL undergoes a marked reduction in size and weight 62 to form an increasingly fibrous avascular structure termed the corpus albicans. Structural 63 regression includes apoptosis of luteal cells, degradation of capillary vessels, and extensive 64 tissue remodeling (4, 5). Tissue remodeling during luteolysis is accompanied by an invasion of 65 the CL by macrophages (6, 7) and proteolytic degradation of the extracellular matrix by matrix 66 metalloproteinases (MMPs) (8) . 67 Although luteal function is fundamentally important in human reproduction, we still do not 68 understand how luteolysis is initiated in the absence of pregnancy. This is because there are no 69 good non-primate animal models that regulate the CL in same way as women. It is believed that 70 a functional withdrawal of LH enhances the expression of paracrine molecules that promote 71 luteolysis and that are suppressed by hCG (9) . We previously demonstrated that a member of 72 6 re-suspended in culture medium (DMEM/Ham's F-12 containing 2 mM L-glutamine, 10 121 unit/mL penicillin, 0.1 mg/mL streptomycin, 2.5 μg/mL amphotericin B, and 1× concentration 122 of ITS-X). Cell suspension was layered over 45% Percoll in culture medium mixture, and 123 centrifuged at 1,200 rpm for 30 min to pellet blood cells.
LGCs, visible in the interface, were 124 collected by a pipette and washed three times with Dulbecco's phosphate buffered saline with 125 MgCl 2 and CaCl 2 . 126
One hundred-thousand viable cells were seeded on Matrigel-coated 24 well plates and 127 cultured with 1 mL of culture medium at 37°C in 5% CO 2 in air. The culture medium was 128 changed every two days, and cells were treated on day six of culture for 8 or 24 hours with 129 either 1) 100 ng/mL hCG, 2) 50 ng/mL BMP2, BMP4, and BMP6 (R&D Systems Inc., 
Quantitative RT-PCR (qRT-PCR) 137
The CLs used for a quantitative gene expression analysis were classified as early-luteal (1-5 138 days after the LH surge, n=4), mid-luteal (6-10 days, n=6), late-luteal (11-14 days, n=6), 139 menstrual phase (over 14 days, n=3), and rescued by hCG injection (n=4). Total RNA was 140 extracted from the frozen human CL or cultured LGCs using RNeasy Mini Kit (Qiagen Ltd., 141
Crawley, UK) following the manufacturer's protocol. RNA (200 ng) was used to prepare cDNA 142 using the TaqMan Reverse Transcription regents (Applied Biosystems, Foster City, CA, USA). 143 The sequences of the primer sets used for this study are listed in The sections were counterstained with haematoxylin and observed under a light microscope 180 (BX51; Olympus corporation, Tokyo, Japan). Identification of granulosa lutein, theca lutein, 181 endothelial and other non-steroidogenic cell types was done using cell localization and 182 morphology with reference to our previous detailed studies using immunohistochemical cell 183 identification in the human CL (4-6, 21, 22). Some sections were immunostained with mouse 184 anti-CD31 antibody (1:20; Dako Japan ltd., Tokyo, Japan) or rabbit anti-3-HSD (1:1,000; kind 185 gift from Prof. Ian Mason, The University of Edinburgh) to identify the endothelial cells and 186 steroidogenic cells, and the reaction site were visualized as described above using appropriate 187 peroxidase or biotin-labeled secondary antibodies. 213 We next investigated the cellular sources of luteal BMPs. Both BMP4 and BMP6 were 214 expressed in the CL, and primarily localized to the cytoplasm of granulosa lutein ( Figures 1F-I ) 215 10 BMP4, while other non-steroidogenic cells and stromal cells outside the CL lacked BMP4 217 immunoreactivity (arrowheads in Figure 1G ). Immunoreactivity for BMP6 was also detected in 218 endothelial cells and stromal cells outside the CL (Figure 1H ), while non-steroidogenic cells in 219 the CL parenchyma were not immunostained (arrowheads in Figure 1I ). Thus BMPs are mainly 220 produced by luteal steroidogenic cells. 
BMPs are autocrine and/or paracrine mediators in luteal cells
HCG reduces luteal BMP and BMP receptor mRNA abundance 235
We next analyzed the effect of hCG, which rescues the human CL from luteolysis, on the 236 mRNA expression of BMPs and the related genes for BMP function. Both BMP2 and BMP4 237 mRNAs were down-regulated by in vivo administration of hCG when compared to the 238 late-luteal CL in the absence of hCG (P<0.001; Figure 3A ). BMP6 mRNA expression also 239 decreased in the rescued CL, however, the suppressive effect of hCG did not reach a significant 240 11 level (P=0.0548; Figure 3A ). In LGCs in vitro, hCG significantly decreased the mRNAs 241 expression of all three BMPs (P<0.001; Figure 3B ). This confirms that the expression of BMP 242 transcripts is hormonally regulated in luteal steroidogenic cells. 243 In addition, hCG reduced the mRNA expression of BMP receptors in cultured LGCs 244 (BMPR1A P<0.05; BMPR1B P<0.01; BMPR2 P<0.05; Figure 3C ). HCG also altered the 245 transcript abundance of other regulators involved in BMP function ( Figure 3D) . Expression of 246 an antagonist for BMPs, GREM2, was up-regulated in LGCs by hCG (P<0.001). In contrast, the 247 other BMP antagonists, NOG (P<0.01) and GREM1 (P<0.001) were decreased by hCG as was 248 an inhibitor of Smad activation, SMAD6 (P<0.05; Figure 3D ). These data suggest that hCG 249 would be consistent with an inhibition of luteal BMP activity by down-regulating the expression 250 of BMPs and their receptors. 
BMPs have a similar effect to Activin on LGC function 269
Activin has an opposite effect to hCG in regulating the function of human LGCs in vitro (11). 270 Administration of hCG increased the expression of LHCGR (P<0.001; There are more than 40 molecules in this superfamily, which are classified into TGF, 292
Inhibin/Activin, BMP, anti-müllerian hormone (AMH), and growth and differentiation factor 293 (GDF) subfamilies. In the ovary, it is well established that most of the TGF superfamily 294 proteins, especially Activins, BMPs, and GDF are involved in the regulation of steroidogenic 295 cells during follicle growth (25-27). However, limited information was available about their role 296 in the CL. We previously demonstrated that Activin A plays an important role in the regulation 297 of luteolysis in women (10, 11). Here we provide the evidence that supports a role for BMPs in 298 the regulation of luteolysis in women. 299 We showed in this study that luteal steroidogenic cells were sites of synthesis and reception 300 of BMPs and that BMP-stimulated cell signaling (p-Smad 1/5/8) was present in these cells. 301 Previously BMP expression in granulosa cells has been shown to be maintained after 302 luteinization in women (15, 16, 28). The present study further demonstrated that BMP4 and 303 BMP6 are localized to both granulosa lutein and theca lutein cells in the CL of women, and that 304
BMPs are able to act on luteal cells in a paracrine and/or autocrine manner. This suggests that 305 locally produced BMPs may have a role in the regulation of the CL as they do during 306
folliculogenesis (25-27). 307
If BMPs have a role in the regulation of the CL, it would be expected that their 308 expression in the CL would change across the luteal phase. We showed that BMP mRNA 309 abundance remarkably changed across the luteal phase: the mRNA expression of BMP2, BMP4, 310 and BMP6 all increased in the late-luteal phase. This would be consistent with that BMPs have 311 an important role during luteolysis. Although the mechanism of luteolysis in rodents differs 312 14 from that in women, the expression of BMP2 and BMP6 in the rodent CL increased at the time 313 of regression (18). This implies that BMP activity during luteolysis may be conserved in 314 disparate species with different paradigms of CL regulation. 315 If BMPs are the molecules with a role in luteolysis in women, it would be expected that 316 hCG, which protects the human CL from luteolysis (9) would further support a potential luteolytic role for BMPs. 323 We have previously shown that Activin A is a paracrine effector of luteolysis (10, 11) and 324 hCG is known to reduce Activin A activity at multiple levels. HCG increased the expression of 325
Follistatin which functions as an antagonist by binding to and inactivating Activins (10). We 326 therefore analyzed the effect of hCG on mRNAs for BMP-specific antagonists expecting that it 327 would up-regulate these genes. Interestingly, the effect of hCG was not consistent. Among 328 BMP-specific antagonists, NOG and GREM1, which were predominantly expressed in human 329 LGCs, were suppressed by hCG. In contrast, GREM2, another BMP-specific antagonist, was 330 significantly up-regulated by hCG although its expression was relatively low. However, overall 331 these results would suggest that BMP signaling is suppressed by hCG in luteal cells via 332 down-regulation of the expression of both BMPs and their receptors. 333 In the human CL the mRNA abundance of BMP2, BMP4 and BMP6 was maximal in the 334 late luteal phase. Interestingly after menstruation had commenced the luteal expression of 335 BMP6 was not maintained in contrast to that of BMP2 and BMP4. While this may be due to the 336 15 different cellular localization of BMP6, which is expressed in non-steroidogenic cells outside 337 the CL as well as luteal steroidogenic cells, we also wondered if the molecular regulation of 338 BMP6 differed to that of BMP2 and BMP4. As hCG can stimulate different intracellular 339 signalling pathways (29), we therefore investigated which pathways regulated the mRNA 340 abundance of the different BMPs. The present study provided the evidence for the first time that 341 the expression of BMP2, BMP4, and BMP6 transcripts in human LGCs are regulated by 342 different intracellular signaling pathways. HCG is classically considered to work through PKA 343 activation (29). Accordingly, blocking of the PKA pathway in vitro led to the expected increase 344 the expression of both BMP2 and BMP4. However BMP6 mRNA abundance was reduced by 345 PKA inhibition suggesting that the PKA pathway may not be involved in the hCG-mediated 346 inhibition of BMP6 in LGCs. 347 HCG is also known to activate PKC (29), and the activation of this pathway reduced 348 BMP6 expression. This suggests that BMP6 mRNA in LGCs may be primarily regulated by 349 PKC activation rather than PKA. Thus, although the effect of hCG is same, it is likely that the 350 reduction of BMP2 by hCG treatment is mainly through PKA, BMP6 is mainly through PKC, 351 and BMP4 is through both PKA and PKC. It is well known that PKC pathway is activated by LGCs. We confirmed the same effects of both BMP4 and BMP6 on the 367 expression of these genes in human LGCs, indicating that BMPs seem to suppress luteinization 368 of human granulosa cells like Activin A (11). Importantly, the factors that regulate follicle 369 growth and suppress luteinization of granulosa cells are also likely to be involved in the 370 suppression of progesterone synthesis in luteal cells during functional luteolysis. 371 We previously showed that Activin A promoted its own synthesis in human luteal cells (11) . 372 This leads to a cycle of positive reinforcement of Activin action during luteolysis. We reported 373
here that BMPs enhance the expression of Inhibin/Activin  subunits in human LGCs, possibly 374 stimulating Activin synthesis in luteal cells and contributing to the increased action of Activin. 375 This is consistent with the previous report showing that BMP up-regulates the production of 376
Inhibin/Activin B subunit in human LGCs (28). It is likely that local Activin synthesis is 377 stimulated by BMPs, however, further work on the resulting Inhibin/Activin balance is required 378 because BMP4 and BMP6 also slightly increased the mRNA expression of Inhibin  subunit 379 (Table 2) . On the other hand, unlike Activin A that enhanced Activin/Inhibin  subunits 380 synthesis, we showed that the mRNA abundance of BMPs was reduced in response to BMPs. 381 The net effect of BMPs is uncertain but there may be a self-limitation in the BMP effect during 382
luteolysis. 383
In conclusion, the expression of BMP2, BMP4, and BMP6 is increased in the regressing 
